{"id":99569,"date":"2022-07-15T11:26:03","date_gmt":"2022-07-15T09:26:03","guid":{"rendered":"https:\/\/www.ioveneto.it\/?post_type=progetti&p=99569"},"modified":"2023-10-30T09:42:45","modified_gmt":"2023-10-30T08:42:45","slug":"innovative-partnership-for-action-against-cancer-ipaac","status":"publish","type":"progetti","link":"https:\/\/www.ioveneto.it\/progetti\/innovative-partnership-for-action-against-cancer-ipaac\/","title":{"rendered":"Innovative Partnership for Action Against Cancer (IPAAC)"},"content":{"rendered":"\n
Leggi in italiano<\/strong><\/a><\/strong><\/p>\n\n\n\n Cancer continues to present one of the key public health challenges in the European Union. Over the last 8 years, we have seen an intensification of the activities at the level of the European Union in order to tackle cancer from different aspects. Still, a number of important outstanding issues in cancer control remain unaddressed. The Innovative Partnership for Action Against Cancer (iPAAC)<\/strong>, which has been selected for funding under the Third Health Programme 2014\u20132020, aims to build upon the outcomes of previous EPAAC and CANCON Joint Actions.<\/p>\n\n\n\n The IOV was involved in the following WPs: The general objective of the iPAAC Joint Action (JA) is to develop innovative approaches to advances in cancer control. The innovation that will be covered within the JA consists of further development of cancer prevention, comprehensive approaches to the use of genomics in cancer control, enhancing cancer information and registries, improvements and challenges in cancer care, anticipation of challenges with innovative cancer treatments and governance of integrated cancer control, including a new analysis of national cancer control plans.<\/p>\n\n\n\n The results of the activities performed within the iPAAC Joint Action are available in the website https:\/\/www.ipaac.eu<\/a> and include:<\/p>\n\n\n\n IOV Researcher: Dr. Annarosa Del Mistro, Immunology and Molecular Oncology Unit<\/strong><\/a><\/strong><\/p>\n\n\n\n Up to 40% of cancer cases diagnosed can be prevented through practices and actions targeted at the individual and population levels. Primary prevention comprehends lifestyle modifications and vaccination programmes, while secondary prevention is now represented by organized cancer screening programmes for bowel, breast and cervical cancers, as indicated in the European Code Against Cancer<\/a>. The activities on cancer prevention of the WP5 have produced documents on early diagnosis, new openings of cancer screening (for lung and prostate cancers), future actions on primary prevention, and recommendations for the sustainability and monitoring of the Code:<\/p>\n\n\n\n IOV Researcher: Dr. Arcangela De Nicolo, Scientific Directorate – Cancer Genetics Program<\/strong><\/p>\n\n\n\n Within the framework of the iPAAC WP6 activities, Dr. De Nicolo contributed to the development of the pilot distance training Oncogenomics<\/em> for health professionals<\/em>, addressed to physicians<\/em> and biologists<\/em>. The course aimed at improving knowledge, attitude, and practice<\/em> of healthcare professionals on the fundamental principles of genetics and on the main applications of current genomic technologies in clinical oncology. The learning method, inspired by the Problem-Based Learning (PBL) approach, encouraged the participants to identify their learning goals by analyzing a problem linked to their professional setting. Video lessons, reading and learning materials guided participants to solve the problem. The course, held in English and with an estimated duration of 16 hours, was delivered through the platform www.eduiss.it<\/a> (from April 8 to December 13, 2021).<\/p>\n\n\n\n
WP 5:<\/strong> Cancer Prevention
WP 6:<\/strong> Genomics in Cancer Control and Care
WP 9:<\/strong> Innovative Therapies in Cancer
WP 10:<\/strong> Governance of Integrated and Comprehensive Cancer Care<\/p>\n\n\n\nExpected results<\/h2>\n\n\n\n
\n
Global goals<\/h2>\n\n\n\n
Results achieved<\/h2>\n\n\n\n
\n
Description of the main WP results the IOV was involved in<\/h2>\n\n\n\n
WP 5: Cancer prevention<\/h3>\n\n\n\n
\n
WP 6: Genomics in Cancer Control and Care<\/h3>\n\n\n\n
WP 9: Innovative therapies in cancer<\/h3>\n\n\n\n